NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.
Alzheimer's and AAMI Reviewed by NeuroPerspective
SAN DIEGO, Sept. 8, 2016 /PRNewswire/ — NI Research has released the September/October issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. Alzheimer's constitutes the single largest opportunity in the pharma world, but it also presents a daunting legacy of clinical disappointments. Logo – http://photos.prnewswire.com/prnh/20160907/405341LOGO The neuroscience area had for some time allowed theory to […]
Depression and Autism Reviewed by NeuroPerspective
SAN DIEGO, March 8, 2016 /PRNewswire/ — NI Research has released the March-April issue of NeuroPerspective, featuring comprehensive reviews of Depression and of Autism. Logo – http://photos.prnewswire.com/prnh/20160307/341407LOGO "Perhaps surprisingly, this may be one of the most optimistic issues NIR has ever produced, despite the angst that has swept the world's financial markets, roiled by intransigent conflicts, […]
Alzheimer's and AAMI Reviewed by NeuroPerspective
SAN DIEGO, Sept. 15, 2015 /PRNewswire/ — NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. Logo – http://photos.prnewswire.com/prnh/20150914/266362LOGO "Alzheimer's constitutes the single largest opportunity in the pharma world, but it also presents a daunting legacy of clinical disappointments. To some degree, the neuroscience area has allowed theory […]
Parkinson's and Neuropathic Pain Reviewed by NeuroPerspective
CARDIFF, Calif., May 6, 2015 /PRNewswire/ — NI Research (NIR) has released the May/June issue of NeuroPerspective, which features comprehensive reviews of two major areas: Parkinson's and Neuropathic Pain. Logo – http://photos.prnewswire.com/prnh/20150505/213986LOGO Parkinson's is one of the major neurodegenerative disorders associated with aging, and while it does not approach the scale of Alzheimer's, approximately one million […]
Alzheimer's Reviewed by NeuroPerspective
CARDIFF, Calif., Sept. 3, 2014 /PRNewswire/ — NI Research (NIR) has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. Logo – http://photos.prnewswire.com/prnh/20140902/142106 "Alzheimer's constitutes the single largest opportunity in the pharma world, but with risk to match, and a daunting legacy of clinical disappointments. It has seen a surprising lack […]
Depression Reviewed by NeuroPerspective
CARDIFF, Calif., May 6, 2014 /PRNewswire/ — NI Research has released the May issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the companies developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine, and has been further invigorated by the […]
Migraine Reviewed by NeuroPerspective
CARDIFF, Calif., April 8, 2014 /PRNewswire/ — NI Research has released the April issue of NeuroPerspective, which reviews and assesses migraine therapeutics in development. Migraine is the most common of all neurological disorders. Based on epidemiological studies done in the US and Europe during the 1990s, approximately 12.6% of the population experiences migraine in a […]
Huntington's Reviewed by NeuroPerspective
CARDIFF, Calif., March 4, 2014 /PRNewswire/ — NI Research has released the March issue of NeuroPerspective, which reviews and assesses the range of neurotherapeutics programs in development for Huntington's Disease. Huntington's is a devastating orphan neurodegenerative disorder known to affect approximately 30,000 patients in the United States, with another 150-200,000 individuals genetically at risk for […]
Alzheimer's Therapeutics Reviewed by NeuroPerspective
CARDIFF, Calif., Sept. 12, 2013 /PRNewswire/ — NI Research (NIR) has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics at http://www.niresearch.com/onlinestore.html. Alzheimer's constitutes the single largest opportunity in the pharma world, but with risk to match. As NeuroPerspective (NP) publisher Harry Tracy PhD notes: "This comes at a time when many of the mechanistic […]
Parkinson's Therapeutics Reviewed by NeuroPerspective
CARDIFF, Calif., May 6, 2013 /PRNewswire/ — NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's. "The current therapeutic options for PD are limited in scope and duration of utility. Motoric symptoms can be attenuated, […]
Schizophrenia and Its Treatment Reviewed by NeuroPerspective
CARDIFF, Calif., March 19, 2013 /PRNewswire/ — NI Research has released the March issue of NeuroPerspective. The issue features a comprehensive review of schizophrenia, with a focus on the progress being made in developing therapies that go beyond the blunting of the hallucinations and delusions that are the signature symptoms of this most devastating of all […]
ALS Reviewed by NeuroPerspective
CARDIFF, Calif., Feb. 11, 2013 /PRNewswire/ — NI Research has released the February issue of NeuroPerspective. The issue features a comprehensive review of ALS, and the continuing but frustrating search for a genuinely useful treatment for the treatment of this devastating illness. "Just as Alzheimer's slowly erases memory and personality, ALS gradually destroys muscle control, leaving […]
Rapid-Acting Antidepressants Reviewed by NeuroPerspective
CARDIFF, Calif., Dec. 11, 2012 /PRNewswire/ — NI Research has released the December issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the programs developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine. This 29-page issue includes: […]
Alzheimer's Therapeutics Reviewed by NeuroPerspective
CARDIFF, Calif., Sept. 6, 2012 /PRNewswire/ — NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. The focus is particularly timely, given the recent release of Phase III results for bapineuzumab and solaneuzumab, which serve as a reminder of how poorly the pharma industry has allocated its […]
Stroke Reviewed by NeuroPerspective
CARDIFF, Calif., May 16, 2012 — NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its May issue, which assesses the field of therapeutics for stroke. "We have been waiting for good news in stroke for a long time, and it remains elusive for pharmacotherapy, where there were two more pivotal trial failures […]
Private CNS Company Review 2012 Released by NI Research
CARDIFF, Calif., March 8, 2012 — NI Research, the publisher of independent and authoritative reviews of the neurotherapeutics area, has released the 2012 edition of the Private CNS Company Review. PCNS provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises […]
